EGFR及MMP-9在上皮性卵巢癌组织中的表达及其与预后的关系

Expression of EGFR and MMP-9 in epithelial ovarian cancer and their correlation with prognosis of patients

目的:研究表皮生长因子受体(EGFR)及基质金属蛋白酶-9(MMP-9)在上皮性卵巢癌中的表达,分析其与卵巢癌临床病理特征及预后的关系。方法:采用RT-PCR方法检测EGFR及MMP-9 mRNA在上皮性卵巢癌、卵巢良性肿瘤和正常卵巢组织的表达。结果:卵巢癌组织中EGFR和MMP-9 mRNA的阳性表达率分别为64.44%(29/45)、73.33%(33/45),相对表达水平为0.81±0.23、0.89±0.25,均明显高于卵巢良性肿瘤和正常卵巢组织,差异均有显著统计学意义(P均<0.05)。两者在有淋巴结转移的癌组织中的相对表达量均明显高于无淋巴结转移组,Ⅲ～Ⅳ期癌组织中的表达高于Ⅰ～Ⅱ期,差异均有统计学意义(P<0.01)。卵巢癌组织EGFR和MMP-9的表达呈显著正相关。Long-rank分析显示,EGFR和MMP-9共同表达患者的累积生存率明显低于阴性者,差异有显著统计学意义(P<0.05)。结论:上皮性卵巢癌组织中EGFR和MMP-9均呈现高表达,并且与卵巢癌的临床分期、淋巴结转移及患者的生存期密切相关,可作为判断上皮性卵巢癌恶性生物学行为和预后的重要参考指标。

Objective：To investigate the expression of epidermal growth factor receptor（EGFR）and matrix metalloproteinase-9（MMP-9）in epithelial ovarian cancer and their correlation with clinical pathological features and prognosis of the patients.Methods：Expression of EGFR and MMP-9 mRNA in ovarian cancers,benign ovarian tumor and normal ovarian tissues were detected by RT-PCR assay.Then the correlation between EGFR and MMP-9 and their relationship with clinical pathological features of ovarian cancer were explored.Results：The rate of expression of EGFR in tumor tissues was 64.44% and MMP-9 was 73.33%,which was significantly higher than that in benign tumors and normal tissues（P0.05）.The expression EGFR and MMP-9 were higher in cancerous tissues with lymphatic metastasis than those without lymphatic metastasis（P0.01）.And their expression in stage Ⅲ～Ⅳ were higher than those of patients in stage Ⅰ～Ⅱ（P0.01）.In epithelial ovarian carcinomas,there was positive correlation between the expression of EGFR and MMP-9（P0.01）.Long-rank analysis indicated the accumulated survival rate of the patients with EGFR and MMP-9 expression was lower than that of patients without their expression（P0.05）.Conclusion：The over-expression of EGFR and MMP-9 in epithelial ovarian cancer is correlated closely with FIGO stage,lymphatic metastasis and survival rate,which could be used as a useful marker of the biological behavior and as a prognosis factor for the patients of ovarian cancer.